The Biomolecular Sciences Institute (BSI) and PREMIER Biosoft are pleased to announce their research collaboration in providing advanced mass spectrometry-based data analysis solutions for lipidomics. PREMIER Biosoft, in collaboration with BSI researcher Dr. Fráncisco Fernández-Lima, associate professor in the Department of Chemistry and Biochemistry and Director of the Advanced Mass Spectrometry Facility at FIU, will work closely to power research in small as well as large molecule identification and quantification. Lipidomics is an emerging field of biomedical research involving the large-scale study and analysis of pathways and networks of cellular lipids in biological systems.

Leading the research efforts in partnership with PREMIER Biosoft, Fernández-Lima will help develop lipidomics’ workflows using the latest in mass spectrometry technologies, including the high-resolution Fourier Transform Ion Cyclotron Resonance (FT-ICR), Data-independent Acquisition (DIA) and Data-dependent Acquisition (DDA). Fernández-Lima’s laboratory features state-of-the-art instrumentation enabling a broad range of analytical approaches, ranging from synthetic small molecule identification and tissue imaging to biological extract characterization.

Fernández-Lima’s research group will contribute their expertise by generating volumes of high-throughput FT-ICR, DIA, and DDA data from different instrumentation platforms to assist PREMIER Biosoft in data interpretation, heuristics, and strengthening the product databases. “Our goal is to push the limits of mass spectrometry by developing an integrated approach involving next generation instrumentation and methodologies that help to establish advanced lipidomics analysis solutions for environmental, biomedical and behavioral research. Our collaboration with PREMIER Biosoft will support this goal and provide the necessary software support to carry out the analysis,” Fernández-Lima said. “The collaboration combines pioneering research from the laboratory of Dr. Fernández-Lima with the unique strength and expertise of PREMIER Biosoft in developing robust mass spectrometry-based software solutions that transform lipidomics research,” said Arun Apte, CEO at PREMIER Biosoft.

This research will help the scientific community to better understand lipid content and dynamics since they have been associated with several human lifestyle-related diseases, such as atherosclerosis, obesity, diabetes, and Alzheimer’s. Lipidomics was recently established as a lipid-related research tool for lipid biochemistry, clinical biomarker discovery, disease diagnosis, and in understanding disease pathology. The current high-throughput workflow will allow a new look at the specific functions of lipid species in health and disease and provide potential biomarkers for establishing preventive or therapeutic programs for human diseases.